GlobalData on MSN8h
FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes
Last July, the agency placed a hold on the trial due to a chromatographic signal detected in a human ADME study of the ...
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial
The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.
vTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment study
Tv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial ...
vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program
Tv Therapeutics (VTVT) announced that the United States Food and Drug Administration has lifted the clinical hold on the cadisegliatin ...
VTv Therapeutics Shares Rise After FDA Lifts Hold on Diabetes Treatment
Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...
Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics
After the FDA lifted the clinical hold on vTv Therapeutics ’ CATT1 trial, the firm called it a “de-risking” event for shares of the company. Alliance Global noted that the c ...
Vtv Therapeutics Shares Halted as FDA Clinical Hold on Diabetes Treatment Lifted
Cadisegliatin, which was paused in the third phase of its CATT1 trial, is taken orally and is designed to target the liver specifically and aims to treat diabetes by improving blood sugar control. VTv ...
vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati ...